BMC Immunol:抗SIRT1自身抗体可作为早期诊断AS和预测髋关节受累的标志物

2018-12-22 MedSci MedSci原创

关于强直性脊柱炎(AS)中的特异性自身抗体的存在知之甚少,本研究旨在探究AS患者的潜在自身抗体谱。结果显示,与健康对照相比,抗SIRT1自身抗体的水平在AS(P <0.001)和银屑病关节炎(PsA)(P <0.01)患者中明显更高,但在类风湿性关节炎(RA)患者中并没有。此外,AS患者中抗NAD依赖性蛋白去乙酰化酶sirtuin-1(SIRT1)抗体的滴度明显高于RA(P <0

关于强直性脊柱炎(AS)中的特异性自身抗体的存在知之甚少,本研究旨在探究AS患者的潜在自身抗体谱。

结果显示,与健康对照相比,抗SIRT1自身抗体的水平在AS(P <0.001)和银屑病关节炎(PsA)(P <0.01)患者中明显更高,但在类风湿性关节炎(RA)患者中并没有。此外,AS患者中抗NAD依赖性蛋白去乙酰化酶sirtuin-1(SIRT1)抗体的滴度明显高于RA(P <0.05)和PsA(P <0.05)患者。此外,髋关节受累患者第一年抗SIRT1(P <0.001)抗体水平显著升高。AS患者的抗SIRT1抗体阳性率为18.9%。

综上所述,该研究结果表明,抗SIRT1自身抗体可作为早期诊断AS和预测髋关节受累的标志物。

原始出处:

Qiongyi Hu, Yue Sun, et al., Anti-SIRT1 autoantibody is elevated in ankylosing spondylitis: a potential disease biomarker. BMC Immunol. 2018; 19: 38.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1974874, encodeId=cdef19e4874a6, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Wed Oct 30 15:01:00 CST 2019, time=2019-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1841339, encodeId=7acb184133988, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Sun Dec 08 01:01:00 CST 2019, time=2019-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1382694, encodeId=fe7e1382694a7, content=<a href='/topic/show?id=1f4e5946422' target=_blank style='color:#2F92EE;'>#早期诊断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59464, encryptionId=1f4e5946422, topicName=早期诊断)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Mon Dec 24 04:01:00 CST 2018, time=2018-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551924, encodeId=b08f15519240a, content=<a href='/topic/show?id=0cb91634355' target=_blank style='color:#2F92EE;'>#sirt1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16343, encryptionId=0cb91634355, topicName=sirt1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Mon Dec 24 04:01:00 CST 2018, time=2018-12-24, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1974874, encodeId=cdef19e4874a6, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Wed Oct 30 15:01:00 CST 2019, time=2019-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1841339, encodeId=7acb184133988, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Sun Dec 08 01:01:00 CST 2019, time=2019-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1382694, encodeId=fe7e1382694a7, content=<a href='/topic/show?id=1f4e5946422' target=_blank style='color:#2F92EE;'>#早期诊断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59464, encryptionId=1f4e5946422, topicName=早期诊断)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Mon Dec 24 04:01:00 CST 2018, time=2018-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551924, encodeId=b08f15519240a, content=<a href='/topic/show?id=0cb91634355' target=_blank style='color:#2F92EE;'>#sirt1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16343, encryptionId=0cb91634355, topicName=sirt1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Mon Dec 24 04:01:00 CST 2018, time=2018-12-24, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1974874, encodeId=cdef19e4874a6, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Wed Oct 30 15:01:00 CST 2019, time=2019-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1841339, encodeId=7acb184133988, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Sun Dec 08 01:01:00 CST 2019, time=2019-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1382694, encodeId=fe7e1382694a7, content=<a href='/topic/show?id=1f4e5946422' target=_blank style='color:#2F92EE;'>#早期诊断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59464, encryptionId=1f4e5946422, topicName=早期诊断)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Mon Dec 24 04:01:00 CST 2018, time=2018-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551924, encodeId=b08f15519240a, content=<a href='/topic/show?id=0cb91634355' target=_blank style='color:#2F92EE;'>#sirt1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16343, encryptionId=0cb91634355, topicName=sirt1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Mon Dec 24 04:01:00 CST 2018, time=2018-12-24, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1974874, encodeId=cdef19e4874a6, content=<a href='/topic/show?id=f145355379' target=_blank style='color:#2F92EE;'>#BMC#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3553, encryptionId=f145355379, topicName=BMC)], attachment=null, authenticateStatus=null, createdAvatar=https://thirdqq.qlogo.cn/qqapp/101173734/363C99735735B7F4CB11D5F78F580525/100, createdBy=aab22500211, createdName=ms3025846204744509, createdTime=Wed Oct 30 15:01:00 CST 2019, time=2019-10-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1841339, encodeId=7acb184133988, content=<a href='/topic/show?id=18bf61953d3' target=_blank style='color:#2F92EE;'>#标志物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=61953, encryptionId=18bf61953d3, topicName=标志物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6ab940, createdName=hukaixun, createdTime=Sun Dec 08 01:01:00 CST 2019, time=2019-12-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1382694, encodeId=fe7e1382694a7, content=<a href='/topic/show?id=1f4e5946422' target=_blank style='color:#2F92EE;'>#早期诊断#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=27, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=59464, encryptionId=1f4e5946422, topicName=早期诊断)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=30bd35, createdName=一叶知秋, createdTime=Mon Dec 24 04:01:00 CST 2018, time=2018-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1551924, encodeId=b08f15519240a, content=<a href='/topic/show?id=0cb91634355' target=_blank style='color:#2F92EE;'>#sirt1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=16343, encryptionId=0cb91634355, topicName=sirt1)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=74808, createdName=quxin068, createdTime=Mon Dec 24 04:01:00 CST 2018, time=2018-12-24, status=1, ipAttribution=)]
    2018-12-24 quxin068